Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2025 07:30 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit...
December 16, 2021 15:23 ET | Source: Rare Diseases International

First-ever United Nations Resolution to Increase Visibility for the 300 Million Persons Living with a Rare Disease

A global grassroots campaign led by persons living with a rare disease and their families has succeeded in securing the adoption of the first-ever UN Resolution on “Addressing the Challenges of...
July 08, 2021 04:00 ET | Source: Dante Labs

Dante Labs commits to ending Rare Disease Odysseys globally through Stripe2be: a patient-centric whole genome based solution tailored for rare disease patients

Stripe2be uses an unbiased approach to Whole Genome Sequencing (WGS) for rare diseases: combining the information submitted from both personal patient records and statements, and using the Dante Labs...
May 18, 2020 08:01 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
May 15, 2020 10:30 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
May 15, 2020 07:30 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
May 04, 2020 08:01 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
April 30, 2020 13:31 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
February 19, 2020 08:02 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March

Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) --...
February 13, 2020 16:30 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Closing of Public Offering of Common Stock

NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...